FindMyKOL
Clinical trialNCT06291064RecruitingPhase 2Interventional

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

SponsorUniversity of ChicagoEnrollment85Triple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purpose of this study is to determine what proportion of participants will achieve complete pathological response with epirubicin+ cyclophosphamide followed by docetaxel +carboplatin. This will also examine the potential of using signals in the blood (biomarkers) to identify resistance to chemotherapy in Nigerian women with triple negative breast cancer (TNBC). All enrollment to this trial will occur at sites in Nigeria. University of Chicago is serving as coordinating center and will be involved in data analysis.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Nigeria
  • Lagos State University Teaching Hospital

    Ikeja, Lagos, Nigeria

    ABIODUN POPOOLA
    Recruiting
  • Lagos University Teaching Hospital

    Yaba, Lagos, Nigeria

    ANTHONIA SOWUNMI
    Recruiting
  • Obafemi Awolowo University Teaching Hospitals Complex

    Ile-Ife, Osun State, Nigeria

    Recruiting
  • University of Ibadan Hospital

    Ibadan, Oyo State, Nigeria

    ATARA NTEKIM
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CapecitabineCarboplatinCyclophosphamideDocetaxelEpirubicin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Mar 2025
Primary completion
30 Jun 2029
Completion
30 Jun 2032
Last update posted
17 Feb 2026
Registered enrollment
85
Registry id
NCT06291064
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.